The FDA approves Samsung Bioepis’ Epysqli (eculizumab-aagh), marking the second US approval for a biosimilar referencing Soliris (eculizumab).
The FDA approved Epysqli (eculizumab-aagh), a biosimilar developed by Samsung Bioepis that references Soliris (eculizumab), for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).1
According to Johns Hopkins Medicine, paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening blood disorder characterized by the destruction of red blood cells, blood clot formation, and impaired bone marrow function. It is closely associated with aplastic anemia. | Image credit: Anusorn - stock.adobe.com
The approval marked the second for an eculizumab biosimilar, following the May 2024 approval of Bkemv (eculizumab-aeeb).2 Epysqli is also the eighth US biosimilar approval for Samsung Bioepis, following biosimilars for etanercept, infliximab, adalimumab, trastuzumab, bevacizumab, ranibizumab, aflibercept, and ustekinumab.3
“The FDA approval of Epysqli as a biosimilar to Soliris marks an important milestone for PNH and aHUS communities since biosimilars have a potential to positively impact patients and healthcare systems by reducing healthcare costs and improving access to treatments,” Christopher Hansung Ko, President and CEO at Samsung Bioepis, said in a statement.1 “Our mission has been, and always will be improving the lives of patients by providing quality-assured, safe and effective biologic medicines, and our work to fulfill this mission is expanding into rare disease areas where patients continue to suffer from limited access to life-enhancing medicines.”
The FDA’s approval of Epysqli was based on extensive evidence showing it is very similar to Soliris, with no significant differences in safety, purity, and potency. A phase 1, randomized, double-blind, 3-arm, parallel group, single-dose study in healthy volunteers (NCT03722329) demonstrated pharmacokinetic (PK) equivalence and comparable pharmacodynamic (PD), safety, tolerability, and immunogenicity profiles between Epysqli and the reference product. Additionally, a phase 3, randomized, double-blind, multicenter, cross-over study in patients with PNH (NCT04058158) showed clinical equivalence in efficacy, safety, PK, and immunogenicity between the 2 drugs.
Eculizumab, a monoclonal antibody and anti-C5 complement inhibitor, is a well-established treatment for PNH and aHUS, rare diseases with an estimated US prevalence of around 50,000 and 5,000 respectively.4 However, approximately 70% of eculizumab-treated patients with PNH are not dosed according to the label, and two-thirds discontinue treatment within an average of 1.5 years, often due to the high cost of treatment.
Biosimilars, which are highly similar to and have no clinically meaningful differences from an existing FDA-approved biologic, have the potential to alleviate financial burdens on the health care system and improve access to biologic therapies. These drugs must meet the same rigorous standards for pharmaceutical quality, safety, and efficacy as their reference products.
Epysqli was approved by the European Commission in May 2023 as the first eculizumab biosimilar in Europe.5 The biosimilar is also approved in the Republic of Korea.
Samsung Bioepis noted that the biosimilar was not approved to treat patients with Shiga toxin E coli–related hemolytic uremic syndrome.
Reference
1. FDA Approves Samsung Bioepis’ EPYSQLI® (eculizumab-aagh) as a Biosimilar to Soliris (eculizumab). News release. Samsung Bioepis; July 22, 2024. Accessed July 22, 2024. https://www.globenewswire.com/news-release/2024/07/22/2916428/0/en/FDA-Approves-Samsung-Bioepis-EPYSQLI-eculizumab-aagh-as-a-Biosimilar-to-Soliris-eculizumab.html
2. Jeremias S. FDA Approves First Eculizumab Biosimilar. The Center for Biosimilars®. May 29, 2024. Accessed July 22, 2024. https://www.centerforbiosimilars.com/view/fda-approves-first-eculizumab-biosimilar
3. Our products. Samsung Bioepis. Updated July 22, 2024. Accessed July 22, 2024. https://www.samsungbioepis.com/en/product/gate.do
4. National Center for Advancing Translational Sciences. Paroxysmal nocturnal hemoglobinuria. Accessed July 22, 2024. https://rarediseases.info.nih.gov/diseases/7337/index
5. Jeremias S. Samsung Bioepis' Eculizumab Biosimilar Approved in Europe. The Center for Biosimilars. May 31, 2023. Accessed July 22, 2024. https://www.centerforbiosimilars.com/view/first-hematology-biosimilar-approved-in-europe
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results
August 21st 2024Celltrion's adalimumab-aaty biosimilar is now accessible for all Costco members, while Amgen sues Samsung Bioepis over the latter’s denosumab biosimilar candidate, and GlycoNex progresses its denosumab biosimilar SPD8 to phase 3 trials.
CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
August 19th 2024CMS announced negotiated prices for 10 drugs under the Inflation Reduction Act (IRA), sparking mixed reactions, with concerns that including drugs facing imminent biosimilar competition could hinder market access to lower-cost alternatives.